Hyloris Pharmaceuticals SA
XBRU:HYL

Watchlist Manager

Hyloris Pharmaceuticals SA

XBRU:HYL

Watchlist

Dividends

Discount Rate

Price: 5.74 EUR -1.03% Market Closed

Market Cap: 160.7m EUR

Have any thoughts about
Hyloris Pharmaceuticals SA?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US		Fubotv Inc NYSE:FUBO	Media
US		Bank of America Corp NYSE:BAC	Banking
US		Palantir Technologies Inc NYSE:PLTR	Technology
US	C	C3.ai Inc NYSE:AI	Technology
US		Uber Technologies Inc NYSE:UBER	Road & Rail
CN		NIO Inc NYSE:NIO	Automobiles
US		Fluor Corp NYSE:FLR	Construction
US		Jacobs Engineering Group Inc NYSE:J	Professional Services
US		TopBuild Corp NYSE:BLD	Consumer products
US		Abbott Laboratories NYSE:ABT	Health Care
US		Chevron Corp NYSE:CVX	Energy
US		Occidental Petroleum Corp NYSE:OXY	Energy
US		Matrix Service Co NASDAQ:MTRX	Construction
US		Automatic Data Processing Inc NASDAQ:ADP	Technology
US		Qualcomm Inc NASDAQ:QCOM	Semiconductors
US		Ambarella Inc NASDAQ:AMBA	Semiconductors

Add Price Alert

Price Target:

Last Price: 5.74 EUR

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

HYL Alert

Hyloris Pharmaceuticals SA

5.74

-0.06 (-1.03%)

52 Week Range	3.3 13.3
Price Target

We'll email you a reminder when the closing price reaches EUR.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Fubotv Inc NYSE:FUBO	US
	Bank of America Corp NYSE:BAC	US
	Palantir Technologies Inc NYSE:PLTR	US
C	C3.ai Inc NYSE:AI	US
	Uber Technologies Inc NYSE:UBER	US
	NIO Inc NYSE:NIO	CN
	Fluor Corp NYSE:FLR	US
	Jacobs Engineering Group Inc NYSE:J	US
	TopBuild Corp NYSE:BLD	US
	Abbott Laboratories NYSE:ABT	US
	Chevron Corp NYSE:CVX	US
	Occidental Petroleum Corp NYSE:OXY	US
	Matrix Service Co NASDAQ:MTRX	US
	Automatic Data Processing Inc NASDAQ:ADP	US
	Qualcomm Inc NASDAQ:QCOM	US
	Ambarella Inc NASDAQ:AMBA	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Hyloris Pharmaceuticals SA

What unique competitive advantages
does Hyloris Pharmaceuticals SA hold over its rivals?

What risks and challenges
does Hyloris Pharmaceuticals SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Hyloris Pharmaceuticals SA.

What unique competitive advantages
does Hyloris Pharmaceuticals SA hold over its rivals?

What risks and challenges
does Hyloris Pharmaceuticals SA face in the near future?

Has there been any significant insider trading activity
in Hyloris Pharmaceuticals SA recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Hyloris Pharmaceuticals SA.

Provide P/S
for Hyloris Pharmaceuticals SA.

Provide P/E
for Hyloris Pharmaceuticals SA.

Provide P/OCF
for Hyloris Pharmaceuticals SA.

Provide P/FCFE
for Hyloris Pharmaceuticals SA.

Provide P/B
for Hyloris Pharmaceuticals SA.

Provide EV/S
for Hyloris Pharmaceuticals SA.

Provide EV/GP
for Hyloris Pharmaceuticals SA.

Provide EV/EBITDA
for Hyloris Pharmaceuticals SA.

Provide EV/EBIT
for Hyloris Pharmaceuticals SA.

Provide EV/OCF
for Hyloris Pharmaceuticals SA.

Provide EV/FCFF
for Hyloris Pharmaceuticals SA.

Provide EV/IC
for Hyloris Pharmaceuticals SA.

Show me price targets
for Hyloris Pharmaceuticals SA made by professional analysts.

What are the Revenue projections
for Hyloris Pharmaceuticals SA?

How accurate were the past Revenue estimates
for Hyloris Pharmaceuticals SA?

What are the Net Income projections
for Hyloris Pharmaceuticals SA?

How accurate were the past Net Income estimates
for Hyloris Pharmaceuticals SA?

What are the EPS projections
for Hyloris Pharmaceuticals SA?

How accurate were the past EPS estimates
for Hyloris Pharmaceuticals SA?

What are the EBIT projections
for Hyloris Pharmaceuticals SA?

How accurate were the past EBIT estimates
for Hyloris Pharmaceuticals SA?

Compare the revenue forecasts
for Hyloris Pharmaceuticals SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Hyloris Pharmaceuticals SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Hyloris Pharmaceuticals SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Hyloris Pharmaceuticals SA compared to its peers.

Compare the P/E ratios
of Hyloris Pharmaceuticals SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Hyloris Pharmaceuticals SA with its peers.

Analyze the financial leverage
of Hyloris Pharmaceuticals SA compared to its main competitors.

Show all profitability ratios
for Hyloris Pharmaceuticals SA.

Provide ROE
for Hyloris Pharmaceuticals SA.

Provide ROA
for Hyloris Pharmaceuticals SA.

Provide ROIC
for Hyloris Pharmaceuticals SA.

Provide ROCE
for Hyloris Pharmaceuticals SA.

Provide Gross Margin
for Hyloris Pharmaceuticals SA.

Provide Operating Margin
for Hyloris Pharmaceuticals SA.

Provide Net Margin
for Hyloris Pharmaceuticals SA.

Provide FCF Margin
for Hyloris Pharmaceuticals SA.

Show all solvency ratios
for Hyloris Pharmaceuticals SA.

Provide D/E Ratio
for Hyloris Pharmaceuticals SA.

Provide D/A Ratio
for Hyloris Pharmaceuticals SA.

Provide Interest Coverage Ratio
for Hyloris Pharmaceuticals SA.

Provide Altman Z-Score Ratio
for Hyloris Pharmaceuticals SA.

Provide Quick Ratio
for Hyloris Pharmaceuticals SA.

Provide Current Ratio
for Hyloris Pharmaceuticals SA.

Provide Cash Ratio
for Hyloris Pharmaceuticals SA.

What is the historical Revenue growth
over the last 5 years for Hyloris Pharmaceuticals SA?

What is the historical Net Income growth
over the last 5 years for Hyloris Pharmaceuticals SA?

What is the current Free Cash Flow
of Hyloris Pharmaceuticals SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Hyloris Pharmaceuticals SA.

P/S
Price to Sales

Current

157

Median

2.5

Industry

Lower than median

Higher than industry value

Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.

P/S

Market Cap

160.7m EUR

Revenue

2.1m EUR

All Countries

Forward Multiples

			Market Cap	P/S
BE		Hyloris Pharmaceuticals SA XBRU:HYL	160.7m EUR	77
JP	N	Nichi-Iko Pharmaceutical Co Ltd TSE:4541	776 550.9T JPY	4 211 733
US		Eli Lilly and Co NYSE:LLY	710.5B USD	17.4
UK		Dechra Pharmaceuticals PLC LSE:DPH	440.4B GBP	578.3
DK		Novo Nordisk A/S CSE:NOVO B	3.3T DKK	12.3
US		Johnson & Johnson NYSE:JNJ	373.5B USD	4.3
US		Merck & Co Inc NYSE:MRK	251.1B USD	4
CH		Roche Holding AG SIX:ROG	202.7B CHF	3.5
CH		Novartis AG SIX:NOVN	183.3B CHF	4.1
UK		AstraZeneca PLC LSE:AZN	162.4B GBP	4.1
IE	E	Endo International PLC LSE:0Y5F	146B USD	63

				Revenue Growth
BE		Hyloris Pharmaceuticals SA XBRU:HYL	Average P/S: 382 954.6 77	2 086%
JP	N	Nichi-Iko Pharmaceutical Co Ltd TSE:4541	4 211 733	22%
US		Eli Lilly and Co NYSE:LLY	17.4	110%
UK		Dechra Pharmaceuticals PLC LSE:DPH	578.3	29%
DK		Novo Nordisk A/S CSE:NOVO B	12.3	77%
US		Johnson & Johnson NYSE:JNJ	4.3	12%
US		Merck & Co Inc NYSE:MRK	4	20%
CH		Roche Holding AG SIX:ROG	3.5	15%
CH		Novartis AG SIX:NOVN	4.1	17%
UK		AstraZeneca PLC LSE:AZN	4.1	35%
IE	E	Endo International PLC LSE:0Y5F	63	N/A

P/S Forward Multiples

Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward

P/S

18.8

2-Years Forward

P/S

3-Years Forward

P/S

3.5

Hyloris Pharmaceuticals SA
XBRU:HYL

P/S
Price to Sales

P/S Forward Multiples

See Also

Company

Help

Tools

Stocks

Hyloris Pharmaceuticals SA XBRU:HYL

P/S Price to Sales

P/S Forward Multiples

See Also

Company

Help

Tools

Stocks

Hyloris Pharmaceuticals SA
XBRU:HYL

P/S
Price to Sales